On September 10, INNOVENT BIO fell 3.11% in regular trading to HK$95.20, with turnover of HK$466 million. The stock has now retreated over 16% from its recent high of HK$112.70, extending a pullback that began after the company reported strong first-half results on August 25.
The decline comes amid broad-based selling pressure across the biotechnology sector. Among peers, Everest Medicines fell 7.24%, 3SBio dropped 3.72%, SKB Bio lost 1.46%, and Akeso slipped 1.10%. Southbound funds have been persistently reducing their INNOVENT BIO holdings, with net outflows recorded in 19 of the past 20 trading days totaling over 31.35 million shares, including a single-day net sell of HK$737 million on September 9.
On the news front, results from the National Medical Insurance Negotiation held September 5-6 remain pending. INNOVENT BIO participated with five products including mazdutide, its key GCG/GLP-1 dual agonist. The outcome of pricing negotiations for these core pipeline assets is a near-term overhang. Meanwhile, the company reported H1 net profit of RMB 1.253 billion, up 50.2% year-over-year, with product revenue surging 56.7% to RMB 8.2 billion.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments